Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00005210

Trial Description

start of 1:1-Block title

Title

A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

Tremelimumab

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

This is a Phase 2, randomized, double-blind, parallel-group study. Subjects with
unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio
to receive either tremelimumab or placebo. Approximately 180 subjects will be enrolled at
study centers in multiple countries. The study consists of a screening period, a treatment
period, and a 90-day follow-up period.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

This is a Phase 2, randomized, double-blind, parallel-group study. Subjects with
unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio
to receive either tremelimumab or placebo.

Randomization will be stratified by EORTC status (low-risk vs high-risk), line of therapy
(second vs third), and anatomical site (pleural vs peritoneal). This study plans to use the
EORTC to stratify subjects into high or low risk groups in order to ensure balanced
randomization to the different treatment groups. For subjects in whom pemetrexed was
contraindicated or not tolerated or not an approved therapy (eg, peritoneal mesothelioma),
prior therapy with a first-line platinum-based regimen is required. Approximately 180
subjects will be enrolled at study centers in multiple countries.

The study consists of a screening period, a treatment period, and a 90-day follow-up period.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00005210
  •   2013/08/16
  •   2013/04/22
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT01843374  (ClinicalTrials.gov)
  •   D4880C00003  (MedImmune LLC)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Unresectable Pleural or Peritoneal Malignant Mesothelioma
  •   C45.0 -  Mesothelioma of pleura
  •   C45.1 -  Mesothelioma of peritoneum
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Tremelimumab
  •   Drug: Placebo
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, caregiver, investigator/therapist, assessor
  •   Placebo
  •   Treatment
  •   Parallel
  •   II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Overall survival (OS) time by treatment arm; time frame: Time from randomization until death due to any cause, assessed up to 3 years.; The primary analysis of OS will be performed after a number of deaths have occurred among the approximately 180 participants randomized. For participants who are alive at the time of the primary analysis or lost to follow-up, OS will be censored on the last date when participants are known to be alive.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Durable disease control rate by treatment arm; time frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years.; Durable DCR is defined as the proportion of participants with best response of complete response (CR), partial response (PR), or stable disease (SD) of ≥ 6 months duration
- Length of progression-free survival by treatment arm; time frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years.; Progression-free survival will be measured from randomization to the first documentation of disease progression or death due to any cause, whichever occurs first.
- Overall response rate by treatment arm; time frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years.; Overall response rate is defined as the proportion of participants with confirmed CR or PR.
- Duration of response by treatment arm; time frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years.; Duration of response will be defined as the duration from the first documentation of objective response (CR or PR) to the first documented disease progression.
- Number of participants reporting any adverse event; time frame: Day 1- 90 days post dose; Any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
- Number of participants with changes in patient-reported outcomes; time frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years.; Patient-reported outcomes as measured by the LCSS-Meso (for disease-related symptoms and health-related QoL), EQ-5D-3L (for health status), and BPI-sf (for pain) will be summarized descriptively; the change from baseline for total score and individual domain scores by treatment arm at each time point will be explored.
- Number of participants reporting any serious adverse event; time frame: Day 1 to 90 days post dose
- Number of participants with anti-drug antibodies; time frame: Week 5; The immunogenicity titer will be reported for samples confirmed positive for the presence of anti tremelimumab antibodies.
- Tremelimumab blood concentration; time frame: Week 5; Tremelimumab concentration data and summary statistics will be tabulated.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   Australia
  •   Canada
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2013/05/31
  •   180
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Inclusion criteria:

- Histologically and/or cytologically confirmed pleural or peritoneal malignant
mesothelioma. Disease not amenable to curative surgery;

- Age 18 and over at the time of consent;

- ECOG Performance status 0-1;

- Previous receipt of 1-2 prior systemic chemotherapies that included first-line
pemetrexed (or anti-folate)-based regimen in combination with platinum agent;

- Recovered from all toxicities associated with prior treatment;

- Measurable disease;

- Adequate bone marrow, hepatic, and renal function;

- Negative screening test results for human immunodeficiency virus (HIV), hepatitis A,
B and C;

- Written informed consent and any locally required authorization (eg, HIPAA in the
USA, EU Data Privacy Directive authorization in the EU) obtained from the
subject/legal representative prior to performing any protocol-related procedures,
including screening evaluations;

- Females of childbearing potential who are sexually active with a nonsterilized male
partner must use a highly effective method of contraception for 28 days prior to the
first dose of investigational product, and must agree to continue using such
precautions for 6 months after the final dose of investigational product;

- Nonsterilized males who are sexually active with a female partner of childbearing
potential must use a highly effective method of contraception from Day 1 through 90
post last dose.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Exclusion criteria:

- Received any prior monoclonal antibody against CTLA-4, programmed cell death 1 (PD1)
or programmed cell death 1 ligand 1 (PD-L1);

- History of chronic inflammatory or autoimmune disease;

- Active, untreated central nervous system (CNS) metastasis;

- History of other malignancy unless the subject has been disease-free for at least 3
years. Non-invasive cancer history (such as carcinoma in situ [CIS] that has been
resected) is allowed;

- Pregnant or breast feeding at time of consent;

- Any condition that would prohibit the understanding or rendering of information and
consent and compliance with the requirements of this protocol;

- Active or history of diverticulitis. Note that diverticulosis is permitted;

- Active or history of inflammatory bowel disease (eg, colitis, Crohn's), irritable
bowel disease, celiac disease or other serious gastrointestinal chronic conditions
associated with diarrhea. Active or history of systemic lupus erythematosis or
Wegener's granulomatosis;

- History of sarcoidosis syndrome;

- Currently receiving systemic corticosteroids or other immunosuppressive medications;

- Subjects should not be vaccinated with live attenuated vaccines within one month
prior to starting tremelimumab treatment;

- The last dose of prior chemotherapy or radiation therapy (with the exception of
palliative radiotherapy) was received less than 2 weeks prior to randomization;

- Any condition that, in the opinion of the investigator, would interfere with
evaluation of the investigational product or interpretation of subject safety or
study results;

- Concurrent enrollment in another clinical study or receipt of an investigational
product within the last 4 weeks (participation in the survival follow-up period of a
study is not an exclusion criterion);

- Employees of the study site directly involved with the conduct of the study, or
immediate family members of any such individuals.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • MedImmune LLC
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Helene Mortimer 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Helene Mortimer 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   304
  •   2013/10/20
* This entry means the parameter is not applicable or has not been set.